Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion

Georg Schmidbauer, Wayne W. Hancock, Barbara Wasowska, Alison M. Badger, Jerzy W. Kupiec-Weglinski

Research output: Contribution to journalArticlepeer-review

Abstract

This study evaluated the efficacy and mode of action of rapamycin (RPM) in a model of accelerated (24-hr) rejection of LBNF1 cardiac allografts in specifically sensitized LEW rats. RPM treatment (0.25 mg/kg/day i.p.) between the day of sensitizing skin grafts (day −7) and subsequent heart (day 0) transplantation (Tx), abrogated fulminant rejection and prolonged cardiac allograft survival to 46±22 days (mean±SD, P

Original languageEnglish (US)
Pages (from-to)933-941
Number of pages9
JournalTransplantation
Volume57
Issue number6
StatePublished - 1994
Externally publishedYes

ASJC Scopus subject areas

  • Transplantation
  • Immunology

Fingerprint Dive into the research topics of 'Abrogation by rapamycin of accelerated rejection in sensitized rats by inhibition of alloantibody responses and selective suppression of intragraft mononuclear and endothelial cell activation, cytokine production, and cell adhesion'. Together they form a unique fingerprint.

Cite this